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Resident fibroblasts at sites of infection, chronic inflammation, or
cancer undergo phenotypic and functional changes to support
leukocyte migration and, in some cases, aggregation into tertiary
lymphoid structures (TLS). The molecular programming that shapes
these changes and the functional requirements of this population in
TLS development are unclear. Here, we demonstrate that external
triggers at mucosal sites are able to induce the progressive differen-
tiation of a population of podoplanin (pdpn)-positive stromal cells
into a network of immunofibroblasts that are able to support the
earliest phases of TLS establishment. This program of events, that
precedes lymphocyte infiltration in the tissue, is mediated by para-
crine and autocrine signals mainly regulated by IL13. This initial
fibroblast network is expanded and stabilized, once lymphocytes are
recruited, by the local production of the cytokines IL22 and lympho-
toxin. Interfering with this regulated program of events or depleting
the immunofibroblasts in vivo results in abrogation of local pathol-
ogy, demonstrating the functional role of immunofibroblasts in
supporting TLS maintenance in the tissue and suggesting novel
therapeutic targets in TLS-associated diseases.
fibroblasts | Sjögren’s syndrome | autoimmunity | tertiary lymphoid
structures
The establishment of TLS (tertiary lymphoid structures) is aphenomenon associated with cancer, infection, and autoim-
munity (1). Within peripheral tissue, in autoimmune conditions
such as primary Sjögren’s syndrome (pSS), TLS form pathogenic
hubs of acquired immune responses that are classically associated
with a Th2 paradigm, ectopic autoantibody production, and the
potential expansion of malignant autoreactive B cell clones (1).
While principally composed of lymphocytes and dendritic
cells, TLS organization is supported by a complex network of
nonhematopoietic stromal cells. These include endothelial cells,
lymphatic vessels, nerves, and immunofibroblasts that closely re-
semble the fibroblastic reticular cells (FRCs) that inhabit second-
ary lymphoid organs (SLOs). These populations form a network
that is believed to support the organization and maintenance of the
immune cells in TLS and have been deemed responsible for local
disease resistance to lymphocyte depletion (2, 3).
Elegant in vivo and in silico studies have revealed the hetero-
geneity of the stromal cell populations in SLOs (4) and demon-
strated that interfering with the podoplanin (pdpn)+/Fibroblast
activation protein 1 (FAP)+ network of immunofibroblasts pro-
foundly affects immune cell homeostasis (5–7). Similar data are
not available in chronic autoimmune conditions where targeting
the pathogenic microenvironment could be envisaged, alongside
immune-cell biological therapy, to induce disease remission.
During embryogenesis, innate lymphoid cells (ILCs) provide
molecular cues for the activation of the resident mesenchyme in
ICAM-1high, VCAM-1high organizer cells (8–10). Thereafter,
lymphocyte migration in the anlagen is responsible for the full
differentiation of FRCs within distinct areas of an SLO. Within
TLS, the molecular requirement for immunofibroblast specifi-
cation is still debated (2), and this hampers the development of
therapeutics aimed at targeting this population in humans.
We and others have previously demonstrated that specific
cytokines might support the acquisition of pathogenic features of
resident fibroblasts (11–15). However, a broader understanding
of the signals involved in TLS mesenchymal specification is still
missing, and definitive proof that targeting activated fibroblasts
might interfere with TLS-associated disease is not available.
Here, we provide evidence that immunofibroblasts in human and
murine TLS are required to support local pathology and support
the production of antinuclear antibodies (ANAs). We show that
human TLS are underpinned by the formation of a network of
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Fig. 1. TLS human fibroblasts are characterized by expression of pdpn, FAP, and adhesion molecules. (A) Immunofluorescence analysis of salivary gland biopsy from
pSS patient stained for pdpn (red), FAP (green), and DAPI (blue). (Scale bar: 250 μm.) (B) viSNE plots of CD45−CD235a−CD11b−EpCAM−CD31− cells from pSS patients’
salivary gland biopsy tissue, analyzed by multicolor flow cytometry. Colors indicate cell expression level of labeled markers (pdpn, FAP, ICAM-1, and VCAM-1). (C)
Principle component analysis (PCA) plot from pdpn+ single-cell PCR data. Data are shown for FAP, ICAM-1, VCAM-1, and CD34 in the 2 clusters identified by hierarchical
clustering analysis. (D) viSNE plots of CD45−CD235a−CD11b−EpCAM−CD31− cells from pSS patients’ salivary gland biopsy tissue, analyzed by multicolor flow cytometry.
Colors indicate cell expression level of labeled markers (CD34). Graphs show differential gene expression data for baff, il7, pdgfrα, cxcl12, pdgfrß, cxcl13, ccl19, ccl21,
il4rα, and il22rα transcripts in FACS-sorted CD34+ and CD34−pdpn+ populations. Data are expressed as mean ± SD (n = 5); *P < 0.05; **P < 0.01; paired t test. (E)
Expression of vcam1, icam1, and pdpn mRNA transcript levels in pSS fibroblasts stimulated in vitro with IL13, TNF, and LTα1β2 (n = 5). Relative quantitation (RQ) was
calculated with unstimulated cells. *P < 0.05; **P < 0.01; one-way ANOVA. Data are represented as mean± SD. (F) Analysis of the percentage of pSS fibroblasts positive
for BrdU flow cytometry staining post in vitro stimulation with IL22, TNF, and LTα1β2 (n = 5). *P < 0.05; one-way ANOVA. Data are represented as mean ± SD.
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immunofibroblasts that express pdpn and FAP and respond in vitro
to stimulation with Th2 cytokines and IL22. In vivo, we demonstrate
the presence of resident immunofibroblast progenitors at the sites
of TLS establishment, whose development is initiated by IL13. We
prove that leukocytes are dispensable for this early phase of priming
but are later required for the expansion of the fibroblast network, in
a process mediated by the expression of IL22 and LTα1β2. Finally,
we show that targeting this microenvironment in vivo, either by
depleting immunofibroblasts or interfering with their cytokine-
dependent developmental pathway, is sufficient to induce abro-
gation of local pathology and silence the humoral autoanti-
body response. As such, we provide evidence that targeting
immunofibroblasts, alongside lymphocytes, could be considered
to achieve long-term remission in chronic inflammatory diseases.
Results
IL13 and IL22 Modulate the Phenotype and Proliferation of the TLS
Immunofibroblasts in Salivary Glands of Patients with pSS. The es-
tablishment of TLS in the salivary glands of patients with pSS is
supported by a fibroblast network that express pdpn and FAP,
identified both by immunofluorescence (Fig. 1A and SI Appen-
dix, Fig. S1) and flow cytometry (Fig. 1B). The development of
this network in human samples, that is similar to the FRC net-
work observed in the SLOs (16), correlates with the severity of
CD45+ immune cell infiltration (SI Appendix, Fig. S1). Single-
cell PCR analysis of the pdpn+ fibroblasts unveiled 2 separate
clusters (1, 2). Cluster 1 was characterized by enrichment for
FAP, ICAM-1, VCAM-1, and CD34 transcripts (Fig. 1C). Given
the overlap between CD34 and ICAM-1/VCAM-1 expression,
CD34 was used as a surrogate marker to sort CD34+ and CD34-
PDPN+ cells, the former being ICAMhigh/VCAMhigh (SI Ap-
pendix, Fig. S1). Interestingly, sorted pdpn+CD34+ cells display
enrichment for transcripts encoding for IL7 and B cell activation
factor (BAFF) while pdpn+CD34− cells showed enrichment for
transcripts encoding for CXCL13, CCL19, and CCL21 (Fig. 1D).
These data suggest that, within the pdpn+ population in humans,
2 subpopulations of stromal cells are present that respectively
support lymphocyte survival and organization within the TLS.
Both populations were found to express receptors for TNFα,
LTα1β2, IL4, and IL13, and for IL22, a cytokine that we pre-
viously demonstrated to be responsible for chemokine expression
in TLS (12) (Fig. 1D and SI Appendix, Fig. S1).
IL13 expression has been previously associated with autoim-
munity (17–22). Interestingly, the in vitro challenge of human
isolated fibroblasts with IL13 significantly increased the expres-
sion of VCAM-1 and, to a lesser extent, pdpn and ICAM-1 in
synergy with TNFα and LTα1β2 (Fig. 1E). On the contrary,
stimulation of the same fibroblasts with IL22 demonstrated the
functional ability of this cytokine to induce cell proliferation
(Fig. 1F). However, IL22 did not induce VCAM-1, ICAM-1, and
pdpn (SI Appendix, Fig. S1). While a certain degree of variability
was observed in the fibroblasts’ response to cytokines in vitro,
our results suggested the possibility that cytokines belonging to
different families exert different and complementary effects on
the resident mesenchyme and cooperate with the TNFα family
members toward the acquisition of an immune-pathogenic phe-
notype during TLS assembly.
Immunofibroblast Activation and Expansion Are Observed During TLS
Formation in a Murine Model of Induced Salivary Gland Inflammation.
We took advantage of a previously described model of TLS as-
sembly, characterized by formation of TLS upon salivary gland
infection of wild-type (wt) mice with AdV5 (108–12 plaque-forming
unit) (23). We demonstrated that progressive lymphocyte aggre-
gation in the salivary glands upon infection (SI Appendix, Fig. S2)
is underpinned by the expansion of a network of (CD45−EPCAM−
CD31−) pdpn+ fibroblasts which are similar to those observed in
humans and precedes lymphocyte infiltration and reverts to
baseline levels upon clearance of the TLS from the tissue (Fig. 2 A
and B and SI Appendix, Fig. S2). This population is characterized
by expression of additional stromal cell markers, such as pdgfrα
and pdgfrß, FAP, ICAM-1, VCAM-1, MadCAM, and RANK-L
(Fig. 2C and SI Appendix, Fig. S2). Pdpn+ fibroblasts were found
to express CXCL13, CCL19, BAFF, IL7, and LTβR (Fig. 2D
and SI Appendix, Fig. S2). Interestingly, subdividing the
pdpn+ population into ICAM-1+/VCAM-1+ or ICAM-1+VCAM-1−
and ICAM-1−/VCAM-1+ unveiled increased expression of
lymphoid chemokines, but not survival factors in the ICAM-1+/
VCAM-1+ (double positive) pdpn+ fibroblasts (Fig. 2E).
All together, these data demonstrate that the expression of pdpn
identifies within both human and murine TLS a heterogeneous
population of immunofibroblasts that are able to support the key
immunological functions of survival and migration/organization
exerted in the SLOs by FRCs (SI Appendix, Fig. S2). As demon-
strated in human TLS fibroblasts, pdpn+ fibroblasts are characterized
by the expression of IL4R, IL13R, and, as previously described, of
IL22R (12), alongside TNFR and LTβR (SI Appendix, Fig. S2) (12).
IL4R Engagement Regulates Stromal Cell Priming in an Animal Model
of TLS Assembly. To dissect in vivo the role of these receptors in
TLS assembly, we induced salivary gland inflammation in mice
deficient for IL4R, IL4, and IL13. We demonstrated that, in
vivo, the deficiency of IL4R or IL13, but not of IL4, resulted in a
failure to up-regulate pdpn+ and to prime resident progenitors
(Fig. 3A and SI Appendix, Fig. S3). Interestingly, this defect was
not accompanied by defective stromal cell proliferation (SI Ap-
pendix, Fig. S3). Instead, IL4R−/− mice displayed defective TLS
assembly, including decreased production of homeostatic che-
mokines (Fig. 3B) and formation of smaller inflammatory foci in
the salivary glands (Fig. 3C). While chemokine expression was
compensated in the absence of IL4R signaling by day 15 post-
infection, autoantibody production was, in the IL4R−/−, com-
pletely abolished (SI Appendix, Fig. S3).
To understand the relevance of IL13 in wild type (wt) animals,
we investigated the expression of this cytokine upon salivary
glands following viral infection in C57/bl6 mice. A rapid in-
duction of IL13, but not of IL4, was observed in these animals in
the early phases of TLS formation (Fig. 3C). IL13+ cells were
localized in the inner part of the developing TLS in C57/bl6 mice
reconstituted with IL13gfp bone marrow (Fig. 3D). Innate lym-
phoid cells were identified as an early source of IL13 (Fig. 3E),
alongside fibroblasts and epithelial cells (Fig. 3F and SI Appen-
dix, Fig. S3). This was confirmed by mixed bone marrow chimera
experiments that demonstrate the conserved ability of mice
reconstituted with IL13gfp bone marrow (deficient for IL13 in
the hematopoietic compartment) to prime resident fibroblasts
(SI Appendix, Fig. S3). Together, these data confirm that priming
of the resident progenitors occurs independently of lymphocyte
infiltration in the TLS and that IL13, but not IL4, is respon-
sible for the early engagement of the IL4R signaling on the
immunofibroblast progenitors. To test this hypothesis, we deliv-
ered recombinant IL13 (rIL13) into murine salivary glands in vivo,
and we found that IL13 alone was able to induce up-regulation of
pdpn, ICAM-1, and VCAM-1 (SI Appendix, Fig. S3).
Immunofibroblast Proliferation Is Dependent on IL22/IL22R Interaction.
Observations in wt mice demonstrated that the pdpn+ fibroblasts
undergo a phase of active proliferation after priming (SI Ap-
pendix, Fig. S4); however, this is not regulated by IL13 or IL4.
We therefore aimed to investigate the molecular mechanism
underpinning this phenomenon.
We previously demonstrated that IL22 regulates CXCL13
expression in TLS (12). Moreover, human fibroblasts isolated
from pSS salivary glands expand in vitro in response to IL22,
suggesting the possibility that this cytokine also mediates fibroblast
proliferation in vivo, during TLS assembly. Murine fibroblasts
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express IL22Rα, and this expression increases significantly in
pdpn+ cells upon viral infection (Fig. 4 A and B). To test the
proliferative ability of IL22, we administered recombinant mu-
rine (m) IL22 to unmanipulated salivary glands in vivo and also
in vitro to isolated pdpn+ fibroblasts. We observed that IL22 was
sufficient to induce proliferation of pdpn+ cells both when ad-
ministered in vivo (Fig. 4C) and in vitro (Fig. 4D). Corre-
spondingly, both IL22- and IL22R-deficient mice presented a
numeric defect in pdpn+ stromal cells that was significant from
day 5 postinfection (Fig. 4E). This defect was accompanied by a
significant decrease in BrdU incorporation by the fibroblasts
(Fig. 4F) and could be reproduced by administering therapeutic
doses of the anti-IL22 antibody to virus-cannulated wt mice (Fig.
4G). Together, these data suggest that, during TLS assembly,
while IL13 mediates the early acquisition of an “activated phe-
notype” of the resident progenitors, IL22 is responsible for the
expansion of this immunofibroblast network.
Priming and Expansion of pdpn+ Fibroblasts in TLS Are Independent
of LTα1β2 and RORγ+ Cells. Full development of FRCs in SLOs is
largely regulated by LTα1β2, provided during embryogenesis by
RORγ+ lymphoid tissue inducer cells21. To investigate the effects
that LTα1β2 and RORγ exert on the identified population of
immunofibroblasts, we induced salivary gland inflammation in Ltßr−/−
and Rorγ−/− mice. Both strains exhibited normal up-regulation of
ICAM-1, VCAM-1, and pdpn and normal proliferation of the pdpn+
fibroblasts up to day 8 p.c. (Fig. 5A and SI Appendix, Fig. S5). In-
terestingly, by day 15 p.c., both strains exhibited a defect in the
number and proliferation of pdpn+ fibroblasts, together with a
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fibroblasts (n = 3) and epithelial cells (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001;
t test. Data are represented as mean ± SD.
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the mean ± SD of 2 independent experiments, with 2 to 3 mice per group.
**P < 0.01; one-way ANOVA.
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reduction in the percentage of the ICAM-1/VCAM-1 intermediate
and high cells (Fig. 5A and SI Appendix, Fig. S5).
During TLS assembly, Ltßr−/− and Rorγ−/−mice failed to express
normal levels of lymphoid chemokines and to form organized foci
upon viral infection (Fig. 5 B–E). These data suggest that, while not
required for priming and expansion of the fibroblastic network,
Ltα1β2- and Rorγ-positive cells play a nonredundant role at the
final differentiation and stabilization of the functional phenotype of
the immunofibroblasts.
Lymphocytes Are Dispensable for pdpn+ Fibroblast Priming but
Required for Expansion and Conversion of the Stromal Network to
a Fully Mature Immune Phenotype. The data generated suggested
that different phases of fibroblast modifications during TLS as-
sembly are regulated by diverse cytokines and depend on the
interaction between fibroblasts and different cell types. To better
understand this phenomenon, we induced TLS formation in
lymphocyte-deficient mice. As expected, Rag2−/− mice infected
with adenovirus failed to induce homeostatic chemokine ex-
pression and exhibited a phenotype similar to that of LtβR−/−
mice (Fig. 5F). However, the analysis of the fibroblast com-
partment in Rag2−/− mice showed an early significant defect in
the expansion of the pdpn+ fibroblasts, not observed in the ab-
sence of the LTβR signal. This defect was significant from day
5 post viral infection (Fig. 5G) and closely mimicked the phe-
notype observed in the IL22R−/− and IL22−/− mice (Fig. 4). In-
terestingly, the early fibroblast priming was maintained in
Rag2−/− (Fig. 5G), confirming that IL13 expression and the en-
gagement of IL4R in the salivary gland at this stage is not de-
pendent on lymphocytes. Accordingly, PCR analysis for IL13 in
the Rag2−/− demonstrated a conserved signal for this cytokine
(SI Appendix, Fig. S5).
Deletion of pdpn+/Fap+ Fibroblasts Abrogates TLS Establishment and
Compromises Establishment of Local Pathology. To finally demon-
strate whether the fibroblast network that we described is re-
quired for TLS assembly and maintenance in vivo, we utilized the
Dm2 mouse to deplete pdpn-expressing cells. Dm2 mice have
been previously used to delete pdpn+ FRCs in SLOs, taking
advantage of the expression of FAP+ on pdpn+ FRCs and the
engineered expression of the diphtheria receptor (DTR) under
the FAP promoter (5, 24, 25).
We firstly demonstrated that, similarly to SLOs, pdpn+ cells in
the TLS forming in both wt mice and Dm2 salivary glands ex-
press FAP (Fig. 6 A and B) and that FAP expression is up-
regulated upon inflammation in viral-infected salivary glands
(Fig. 6 C and D). We then treated Dm2 mice with diptheria toxin
as previously described (5, 24, 25) before the induction of TLS
(Materials and Methods). By day 8 postinfection in Dm2+, but not
in control treated mice, there was a significant loss of pdpn+
stromal cells in the salivary gland (Fig. 6E and SI Appendix, Fig.
S6); this effect was associated with a reduced number of lym-
phocytes (Fig. 6F and SI Appendix, Fig. S5), less organized TLS
(Fig. 6G and SI Appendix, Fig. S6), and low chemokine expres-
sion in infected glands (Fig. 6H). Local disaggregation of TLS
resulted in abrogated autoantibody production (Fig. 6I). Given
the potential interference of FAP systemic deletion on the im-
mune response (5), we performed local deletion of FAP+ cells by
delivering DTX directly in the salivary glands. Infected mice
treated with local DTX also display loss of pdpn+ fibroblasts and
a decrease in CD45+ cells, activated T cells, and B cells (SI
Appendix, Fig. S6). Overall, local stromal cell depletion was less
efficient than systemic and was reflected in the lack of impact on
ANA production in treated mice.
Discussion
TLS form in response to the immunological requirement to
generate a local immune response against invading pathogens
and local antigens (26). However, TLS persistence in autoim-
mune conditions correlates with worse outcome, including the
development of MALT (mucosal-associated lymphoid tissue)
lymphoma and increased systemic manifestations (1). Resistance
to immune-cell depletion in subsets of patients with TLS-
associated autoimmune conditions has been linked to the in-
ability to interfere with local excess of survival factors and cy-
tokines produced within the TLS. This suggests that the
identification of the molecular mechanisms responsible for the
establishment and maintenance of this local microenvironment
could be exploited therapeutically (2). Here, we demonstrate
that TLS assembly, both in humans and in an animal model of
TLS, is underpinned by the formation of a network of pdpn+
immunofibroblasts, phenotypically and functionally similar to
the FRC networks described within SLOs. Interestingly, mu-
rine and human fibroblasts display differential associations
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Fig. 5. LTα1β2 and RORγ+ cells regulate chemokine expression but not early
fibroblast priming or expansion. (A) Time course flow cytometry analysis of the
percentage of pdpn+ fibroblasts from wt (black squares, n = 3 to 5), Rorγ−/−
(open squares, n = 3 to 5), and Ltßr−/− (gray squares, n = 3 to 5) mice. *P < 0.05;
one-way ANOVA. Data are represented as mean ± SD. (B and C) Analysis of
cxcl13 and ccl19 mRNA transcripts by qRT-PCR in wt (black bars, n = 7 to 12),
Rorγ−/− (open bars, n = 4 to 5), and Ltßr−/− (gray bars, n = 4 to 7) mice at days 5,
8, 15, and 23 p.c. *P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA. Data are
represented as mean ± SD. (D and E) Immunofluorescence of salivary glands
(day 15 p.c.) from wt, Ltßr−/−, and Rorγ−/− mice [CD3, red; CD19, blue; CXCL13
(D) or CCL21 (E), green]. (Scale bars: 100 μm.) (F) qRT-PCR analysis of cxcl13 and
ccl19 mRNA fromwt (black bars, n = 4 to 6) and Rag2−/− (white bars, n = 4 to 6)
salivary glands at days 5, 8, 15, and 23 p.c. *P < 0.05; **P < 0.01; ***P < 0.001;
one-way ANOVA. Data are represented as mean ± SD. (G) Time course flow
cytometry analysis of the percentage of pdpn+ fibroblasts from wt (black
squares, n = 4 to 6) and Rag2−/− (open squares, n = 4 to 6) mice. *P < 0.05;
**P < 0.01; one-way ANOVA. Data are represented as mean ± SD.
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between expression of chemokines and survival factors and
expression of ICAM-1, VCAM-1, and CD34. The develop-
mental imprinting underpinning these differences is currently
under investigation.
The cellular requirements and microenvironmental signals
responsible for the formation of this fibroblast network, both in
humans and mice, appear to be conserved across species and
unique to TLS and encompass the engagement of Th2 cytokines
and IL22, in synergy with LTα1β2. The analysis of this cascade
and the cellular interaction responsible for it demonstrates that
lymphocytes are dispensable for the early priming of the
immunofibroblast progenitors in TLS. Lymphocytes are, how-
ever, required for the expansion of the network and for its full
conversion to an immune phenotype.
Genome-wide association studies have previously identified
MHC class II haplotypes and components of the IL4/IL13
receptor complex, including Tyk2, as independent risk factors in
immune-mediated inflammatory diseases (27, 28). This risk was
classically associated with the role of the IL4R pathway in CD4 T
cell function. However, MHC class II, the IL4/IL13 receptor
complex, and Tyk2 expression are expressed and functional in
nonhematopoietic cells, including smooth muscle cells. Moreover,
IL4R activation is known to regulate adult muscle regeneration
(29). Previous reports have suggested the association between
IL13 and the production of autoantibodies (17–22). Nevertheless,
no functional proof of this relationship has been provided outside
the role of this pathway in B and T cell regulation (30). Here, we
demonstrate that the release of IL13 by resident ILCs and stromal
cells, including fibroblasts and epithelium, directly regulates phe-
notypical changes but not proliferation of a population of pdpn+
immunofibroblast progenitors. This IL4R-mediated priming is re-
quired for the up-regulation of adhesion molecules, in particular
VCAM-1, that enable the interaction of the fibroblasts with in-
coming leukocytes. IL13 production by resident stromal cells
strongly assimilates this intrinsic and rapid response with the
mechanisms of immunosurveillance ascribed to this cytokine in
carcinogenesis (31). In this latter model, IL13 regulated the release
of thymic stromal lymphopoietin and IL33, thereby accelerating
epithelium repair (31). In our example, IL13 acts on a resident
population of fibroblasts, modulating their ability to interact with
incoming immune cells and form TLS. Together, these observations
provide evidence in support of a critical role of IL13 in response to
external danger signals in a series of pathogenic settings that extend
from inflammation to autoimmunity and cancer.
Intriguingly, IL4R engagement was not able to induce fibro-
blast proliferation. FRC expansion postimmunization has been
described in SLOs and deemed dependent on LTα1β2 and IL4R
(32–34). Here, we demonstrate that, in TLS, expansion of pdpn+
fibroblasts also occurs, with active stromal cell proliferation
peaking at day 5 postinfection. However, this phenomenon is
largely independent of LTα1β2 and RORγt+ cells, but regulated
by lymphocytes and IL22, a cytokine known to promote stromal
cell repair and proliferation (35–38). The biological effect de-
scribed here in murine and human fibroblasts, together with our
previous report on the link between IL22 and CXCL13 expres-
sion in TLS, strongly advocates for an intervention against this
cytokine in clinical practice.
Interestingly, RORγt-dependent IL17 production appears not
to play a major role in this system as a fairly conserved expansion
of the immunofibroblasts occurs, along with TLS formation in
RORγt−/− mice. Whether this is a feature specific of the TLS
forming at mucosal sites is not clear as IL17 production has been
deemed important for TLS establishment in other organs (13–15).
We previously demonstrated that interfering in vivo with
IL22 expression by the use of a blocking antibody profoundly
affects TLS maintenance in the tissue (12). Here, we expanded
this observation and reported the formation of aberrant TLS
with decreased immunofibroblast proliferation in mice treated
with anti-IL22 antibodies, but also in mice deficient for IL4R and
in a model of fibroblast depletion in vivo (Dm2). Previous work
demonstrated that stromal cell depletion in SLOs of Dm2 mice
only marginally affects lymphoid organ architecture (5). How-
ever, the impact on immune effector functions of Dm2 mice
with diphtheria toxin demonstrates that systemic depletion of
immunofibroblasts in TLS exerts a more profound effect, se-
verely compromising aggregate assembly, inducing loss of ana-
tomical organization, diminishing lymphocyte recruitment, and
resolution of tissue pathology. Importantly, in this model and,
similarly, in the absence of the IL4R or IL22R signaling, a re-
duction in the production of antinuclear antibodies was ob-
served. These observations highlight the importance of a normal
fibroblast network to support autoantibody production. Stromal
cell depletion, induced by local DTX delivery, was less efficient
in depleting immunofibroblasts. However, it still profoundly af-
fected local pathology, but not systemic ANA production in viral
infected animals.
Several reports have highlighted the association between
failure to respond to B cell-depleting therapies and the persis-
tence of TLS in the tissue of patients with autoimmune condi-
tions (39–47). These observations establish a pathogenic role for
TLS and their local microenvironment to sustain pathology.
Here, we have demonstrated that the formation of a network of
immune fibroblasts in TLS is responsible for the establishment of
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Fig. 6. Depletion of FAP+ fibroblasts impairs the formation of TLS. (A) Im-
munofluorescence staining of FAP (red) and DAPI (gray) in wt salivary glands at
days 0 and 15 p.c. (Scale bars: 200 μm.) (B) Representative flow cytometry plot
of FAP expression by pdpn+ fibroblasts. The gate shows percentage of FAP+
pdpn+ cells. (C) Time course analysis of the percentage of pdpn+ FAP+ fibro-
blasts in wt mice. Data are presented as mean ± SD. (D) Analysis of fap mRNA
transcript by qRT-PCR in wt salivary glands at days 0, 2, 5, and 15 p.c. (n = 4 to
9). *P < 0.05; ***P < 0.001; one-way ANOVA. Data are represented as mean ±
SD. (E) Flow cytometry data for absolute numbers of pdpn+ fibroblasts at day
8 p.c. in Lm DTX treated (black bars, n = 8) and Dm2 DTX treated (red bars, n =
6). ***P < 0.001; t test. Data are represented as mean ± SD. (F) Flow cytometry
data for absolute numbers of T and B lymphocytes at days 8, 15, and 23 p.c. in
Lm DTX treated (black squares) and Dm2 DTX treated (red bars). Data are
represented as mean ± SD of 2 independent experiments with at least 3 mice
for each experiment. **P < 0.01; one-way ANOVA. (G) Immunofluorescence
staining of CD3 (red) and CD19 (blue) in Lm DTX treated and Dm2 DTX treated
at day 8 p.c. (Scale bars: 100 μm.) (H) qRT-PCR analysis of cxcl13 and ccl19 mRNA
from Lm DTX treated (black bars, n = 6) and Dm2 DTX treated (red bars, n = 4)
salivary glands at day 8 p.c. Data are represented as mean ± SD. (I) Percentage
of positive mice for ANA in lm DTX treated (black bar) and Dm2 DTX treated
(red bar) experimental groups at day 23 p.c.
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the TLS pathogenic microenvironment and that interfering with
the signals responsible for its establishment profoundly affects
local pathology and interferes with autoantibody production,
providing a strong rationale for targeting immunofibroblasts in
the treatment of TLS-associated diseases.
Materials and Methods
Study Design. Immunohistochemistry, immunofluorescence (IF), and flow
cytometry were used to define the phenotype of immunofibroblasts in the
salivary glands of patients with pSS. Tissue was obtained from patients
recruited in the OASIS cohort (Optimising assessments in Sjögren’s syn-
drome) at University of Birmingham under ethics no. 10-018.
IL13, IL4, and IL22 receptor expression was detected in both humans and
mice, and differential biological effects were observed in fibroblasts stimu-
lated with these molecules. To dissect these effects in vivo, we studied the
dynamic response of a population of pdpn+ cells in a model of TLS assembly
in wt mice and in mutants defective for IL13, IL4R, IL4, IL22, IL22R, LTβR, and
Rorγ, as well as Rag2 mice. Mice were maintained in the Biomedical Service
Unit at the University of Birmingham according to Home Office and local
ethics committee regulations (University of Birmingham), under license no.
P4B291FAA. IF, flow cytometry, and qRT PCR were used to assess differential
effects in these mutants in the salivary glands of mice killed at different time
points. Recombinant proteins for the molecules of interest and a blocking
antibody against IL22 were used in gain- or loss-of-function experiments to
dissect the requirements of these pathways in fibroblast maturation and TLS
formation. Finally, to prove the effect that pdpn+ fibroblast deletion would
exert on TLS, we used DM2 mice that express the diphtheria toxin receptor
under the FAP promoter.
Detailed materials and methods can be found in SI Appendix.
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